Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Due to a calculation error in the merger ratio, the shareholder meeting discarded the merger proposal between Alteogen’s subsidiaries (Altos Biologics and Alteogen Healthcare), leading to the complete revocation of the merger and associated stock acquisition decisions.
📊 [Key Disclosure Details & Financial Highlights]
- Target Subsidiary: Altos Biologics Corp. (CEO: Hee Jeong Ji, Main Business: Biopharmaceutical R&D, Major Subsidiary: Yes)
- Subsidiary Total Assets: KRW 63.59B (24.83% of parent company’s consolidated total assets of KRW 256.10B)
- Revoked Items:
- Revocation of Merger Decision (Major Management Matter of Subsidiary)
- Revocation of Decision on Acquisition of Shares and Investment Certificates of Other Corporations
- Reason for Revocation: A calculation error in the merger ratio within the agreement executed on November 14, 2024, was identified, leading to the rejection and discard of the agenda at the shareholders meeting held on November 29, 2024
- Result of Revocation: All scheduled merger timelines between subsidiaries and Alteogen’s associated share acquisition decisions have been cancelled
- Decision Date: 2024-11-29
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Tracking Subsequent Official Filings and Periodic Reports Post-Revocation
This filing documents the official cancellation of the planned subsidiary merger at the shareholders meeting stage due to a merger ratio calculation error. Verifying whether updated status regarding the subsidiaries is reflected in upcoming official reports is important to track the final reporting updates following the cancellation. Further details can be reviewed in future major management disclosures or upcoming periodic business reports.
📢 Disclaimer & Source Information
Source: This content was structured and generated based on official submission data from the Financial Supervisory Service’s Data Analysis, Retrieval and Transfer System (DART).
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For inquiries regarding regulatory compliance or copyright requests, please contact ksb220805@gmail.com.
